Cadila Healthcare Gujarat facility clears USFDA inspection

"We hereby inform that the USFDA inspected the Company’s topical manufacturing facility located in Ahmedabad from 16th to 20th December 2019," Cadila said in a filing

Ahmedabad: Pharma major, Cadila Healthcare recently informed the bourses that the company's topical manufacturing facility in Gujarat has cleared the US drug regulator's inspection.

The US Food and Drug Administration (USFDA) inspected the topical manufacturing facility located in Ahmedabad from 16th to 20th December 2019.

"We hereby inform that the USFDA inspected the Company’s topical manufacturing facility located in Ahmedabad from 16th to 20th December 2019," Cadila said in a BSE filing

At the end of the inspection, no observation (483) is issued," the company added.

Also Read: Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

Cadila Healthcare was founded in 1952 by Ramanbhai Patel, formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. It evolved over the next four decades into an established pharmaceutical company.

Also Read: Zydus Cadila files NDA with DCGI for liver disease drug Saroglitazar Magnesium